This valuation of Bruker Corporation (BRKR) stock follows the requested methodology, using data directly from SEC filings and earnings call transcripts.

---

## 1. Initial Financial Data (as of September 30, 2025)

The base financial figures are drawn from the company's latest available SEC filings (Q3 2025).

| Metric | Value (in millions USD) | Source/Calculation |
| :--- | :--- | :--- |
| **Current Stock Price** | **$39.00** | Conservative approximation based on recent trading. |
| **Shares Outstanding** | **151.7 million** | Most recent share count. |
| **Total Cash & Cash Equivalents** | **$293.1 million** | Cash, Equivalents & Short-term Investments from Q3 2025 balance sheet. |
| **Net Debt** | **$1,717.9 million** | Q3 2025 Net Debt position. |
| **Total Debt** | **$2,011.0 million** | Calculated as: Net Debt ($1,717.9M) + Cash & Equivalents ($293.1M). |

---

## 2. Bruker's Business Engine and Future Projections (2025-2030)

The valuation is highly dependent on a conservative, justified projection of the company's revenue and profitability. Bruker's business is driven by the sale of high-performance scientific instruments, primarily in the life science research and materials analysis markets.

**Business Engine Drivers:**

1.  **Life Science Tools (The Growth Engine):** The company is prioritizing "innovative spatial biology, proteomics, and multiomics solutions" for drug discovery and disease biology research. This area is positioned for strong, above-market growth.
2.  **Aftermarket Revenue (The Stable Engine):** Aftermarket revenue (service, parts, and consumables) exceeded 30% of Bruker Scientific Instruments (BSI) revenues in FY 2024, providing a stable, high-margin revenue base.
3.  **Cyclical Headwinds and Recovery:** FY 2025 is impacted by a slowdown in the academic/government research market, resulting in a guided **4% to 5% organic revenue decline** for the full year. Management expects a "partial recovery in research instruments" in FY 2026 and is "very committed to significant margin expansion and EPS growth... beyond." The Q3 2025 book-to-bill ratio > 1.0 for BSI supports a near-term revenue recovery.

**Conservative Revenue Estimates (in millions USD):**

| Year | Revenue (USD M) | Organic Growth Rate | Justification |
| :--- | :--- | :--- | :--- |
| **2024A** | **$3,370** | *4.0%* | Based on prior year reported revenue. |
| **2025E** | **$3,425** | *1.6% Reported* | Midpoint of management's FY 2025 guidance ($3.41B to $3.44B), reflecting organic decline (-4.5%) partially offset by M&A and FX tailwinds. |
| **2026E** | **$3,682** | *7.5%* | Assumes a *partial recovery* as guided. Revenue growth is driven by catching up on delayed 2025 orders and a conservative **+6%** organic growth in BSI/BEST, plus a conservative 1.5% M&A/FX contribution. |
| **2027E** | **$3,939** | *7.0%* | Reflects a return to long-term organic growth. The 7.0% growth is a blend of high single-digit growth in life sciences (proteomics/multiomics) and steady growth in other segments (material science, aftermarket). |
| **2028E** | **$4,215** | *7.0%* | Continuation of core organic growth driven by new innovative product cycles. |
| **2029E** | **$4,468** | *6.0%* | Conservative deceleration of growth as the business matures. |
| **2030E** | **$4,691** | *5.0%* | Further conservative deceleration, aligning with a mature, high-tech industrial average growth rate. |

**Conservative Margin Estimates:**

The business engine calls for **significant margin expansion** post-2025. Q4 2024 Non-GAAP Gross Margin was 52.5%. Non-GAAP Operating Margin in Q3 2025 was 12.3%, but suffered from "lower revenue absorption, additional tariff costs."

*   **Gross Margin:** Will be projected to recover from a Q3/2025 low (which led to GAAP operating loss) back to the **52.5%** range by 2027 and grow to **54.0%** by 2030, driven by higher-margin services and next-gen product mix (spatial biology).
*   **Net Income Margin:** The FY 2025 non-GAAP EPS midpoint of $1.875 on an estimated $3.425B revenue and 151.7M shares implies a net income of **$284.4M**, resulting in a **8.3% Net Income Margin** for 2025. This is lower than prior years due to the revenue/cost headwind. This margin is projected to expand significantly as the company realizes its cost-savings initiatives (announced in Q2 2025, expected to save $100M-$120M in FY 2026) and revenue recovers.

| Year | Net Income Margin | Justification |
| :--- | :--- | :--- |
| **2025E** | **8.3%** | Based on midpoint of non-GAAP EPS guidance. |
| **2026E** | **10.5%** | Significant jump reflecting cost-saving realization and initial revenue recovery. |
| **2027E** | **11.5%** | Continued margin expansion from operating leverage and higher-margin product mix. |
| **2028E** | **12.5%** | Approaching historical highs for the industry average, reflecting the full impact of new growth drivers. |
| **2029E** | **13.0%** | Conservative mature margin target. |
| **2030E** | **13.5%** | Conservative mature margin target. |

---

## 3. Projected Net Income and Cash Flow (2025-2030)

**Assumptions:**

*   **Net Income to Cash:** Net income for each year goes straight into cash for the next year.
*   **ROIC (Return on Invested Capital):** Historical ROIC has been volatile, ranging from 1.83% to 9.3% TTM. Given the mandate for a *conservative but reasonable positive ROIC %* and the expectation for positive Net Income, a conservative, long-term rate of **6.0%** is used. This is less than the 3-year average of 9.3%.
*   **Cash Flow Formula:** *Projected Net Income* = (Net Income from that year based on margin) + (Accumulated Cash from Prior Years * ROIC).

| Year | Revenue (A) | Net Inc. Margin (B) | Net Income from Operations (A*B) | Prior Year Accumulated Cash | ROIC on Cash (6.0%) | Total Net Income / Cash Flow |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **2025E** | 3,425 | 8.3% | 284 | 293.1 | 17.6 | **301.6** |
| **2026E** | 3,682 | 10.5% | 387 | 301.6 | 18.1 | **405.1** |
| **2027E** | 3,939 | 11.5% | 453 | 405.1 | 24.3 | **477.3** |
| **2028E** | 4,215 | 12.5% | 527 | 477.3 | 28.6 | **555.6** |
| **2029E** | 4,468 | 13.0% | 581 | 555.6 | 33.3 | **614.3** |
| **2030E** | 4,691 | 13.5% | 633 | 614.3 | 36.9 | **670.3** |
| *All figures in millions USD* | | | | | | |

---

## 4. Discounted Cash Flow (DCF) Analysis

**Assumptions:**

*   **Discount Rate (Conservative but Reasonable):** **9.0%** (This is a reasonable WACC for a technology-focused instrument maker with a high beta).
*   **Maturity (Terminal) Rate (Very Conservative):** **3.0%** (Well below long-term GDP growth, reflecting an ultra-conservative view of perpetual growth for the scientific instrument market).

### A. Net Present Value (NPV) of Cash Flows (2025-2030)

| Year (t) | Cash Flow (USD M) | Discount Factor (1/(1.09)^t) | Discounted Cash Flow (USD M) |
| :--- | :--- | :--- | :--- |
| **2025** | 301.6 | 0.917 | 276.5 |
| **2026** | 405.1 | 0.842 | 341.1 |
| **2027** | 477.3 | 0.772 | 368.5 |
| **2028** | 555.6 | 0.708 | 393.4 |
| **2029** | 614.3 | 0.650 | 399.2 |
| **2030** | 670.3 | 0.596 | 399.6 |
| **NPV of Cash Flows (2025-2030)** | | | **2,178.3** |

### B. Terminal Value (TV)

The Terminal Value represents the value of all cash flows beyond 2030.

*   **TV Formula:** [Cash Flow (2030) * (1 + Maturity Rate)] / (Discount Rate - Maturity Rate)
*   TV = [670.3 * (1 + 0.03)] / (0.09 - 0.03)
*   TV = [680.4] / 0.06 = **$11,340.0 million**

### C. Net Present Value (NPV) of Terminal Value

*   **NPV(TV) Formula:** Terminal Value / (1 + Discount Rate)^(Year of Final CF)
*   NPV(TV) = $11,340.0 million / (1.09)^6
*   NPV(TV) = $11,340.0 million / 1.677
*   NPV(TV) = **$6,762.5 million**

### D. Total Equity Value

*   **Total Enterprise Value (TEV):** NPV of Cash Flows + NPV of Terminal Value
*   TEV = $2,178.3 million + $6,762.5 million = **$8,940.8 million**
*   **Total Equity Value:** TEV + Current Cash & Equivalents - Total Debt
*   Total Equity Value = $8,940.8 million + $293.1 million - $2,011.0 million = **$7,222.9 million**

---

## 5. Fair Value Calculation and Justification

*   **Fair Value per Share:** Total Equity Value / Shares Outstanding
*   Fair Value per Share = $7,222.9 million / 151.7 million shares = **$47.61**

### Final Valuation Summary

| Metric | Value |
| :--- | :--- |
| **Calculated Fair Value per Share (DCF)** | **$47.61** |
| **Current Market Price per Share** | **$39.00** |
| **Difference** | **$8.61 (22.1% Higher)** |

### Justification for Difference

The calculated fair value of **$47.61** is **22.1% higher** than the current market price of $39.00. This suggests that the market is making more pessimistic assumptions about the company's future growth and profitability than the conservative model presented here.

**Why the Market is More Conservative (Lower Price):**

1.  **Near-Term Organic Decline:** The market is heavily penalizing Bruker for the guided **4% to 5% organic revenue decline** in FY 2025. This decline is a sharp departure from the company's historical growth and is likely leading to short-term pessimism, overshadowing the long-term potential.
2.  **Margin Headwinds and GAAP Loss:** The market is reacting negatively to the Q3 2025 GAAP operating loss and the significant drop in non-GAAP operating margin (down 260 bps year-over-year). The market may doubt management's ability to achieve "significant margin expansion" in a timely manner.
3.  **High Debt and Dilution:** The recent capital raise through mandatory convertible preferred stock (used to pay down debt) and the associated share count increase are likely creating a near-term overhang. The market is concerned with the relatively high debt load of **$2.011 billion**.

**Why the Conservative DCF is Higher (The Case for $47.61):**

The valuation is backed by a conservative belief in:
1.  **Recovery and Business Engine Strength:** The model assumes the current organic decline is a temporary, cyclical slump in the academic market, as indicated by the **book-to-bill ratio for Scientific Instruments being greater than 1.0** in Q3 2025. This is a strong indicator of future revenue recovery in 2026.
2.  **Conservative Margin Expansion:** The model projects Net Income Margin growing to **13.5%** by 2030, which is achievable through a combination of the announced **$100M-$120M cost savings initiative** and the favorable mix shift to higher-margin, innovative products in the spatial biology and proteomics segments.
3.  **Very Conservative Terminal Rate:** Using a **3.0%** perpetual growth rate is highly conservative. If the company achieves the long-term growth promised by the proteomics and multiomics revolution, the terminal value is likely much higher.

In conclusion, the market is focused on the negative near-term 2025 organic revenue and margin trends, while the DCF model recognizes this as a temporary blip, projecting a conservative but justified recovery and long-term operating leverage based on management's guided internal metrics and business drivers. The fair value of **$47.61** reflects the intrinsic value of a business expected to successfully navigate its current cyclical downturn and realize its planned margin and growth expansion.